Results of Emollient Therapy in a Child with Severe Atopic Dermatitis Treated with Genetically Engineered Biological Drug: Clinical Case

Background. Baseline therapy for children with severe atopic dermatitis (AD) is crucial for achieving required clinical effect, regardless the systemic treatment variants. Clinical case description. The boy, 9 years old, had complaints on widespread rashes on the body and limbs accompanied by dry skin and itching and was diagnosed with AD. Topical glucocorticoids, course of local medium wave narrowband phototherapy of 311 nm, topical calcineurin inhibitors were used in the treatment but with weak positive dynamics. Genetically engineered biological therapy was initiated due to frequent relapses and lack of disease control. No persistent improvement was noted after 10 weeks of therapy. The child was hospitalized, cyclic biological therapy was continued, topical therapy was corrected, and skin care was modified, the emollient-plus drug was prescribed. Clinically significant decrease in EASI and CDLQI indices, as well as a decrease in SCORAD and NRS scores was noted 4 weeks after treatment correction and emollients implementation. Conclusion. Emollients are mandatory in the management of children with AD (despite the disease severity) according to clinical guidelines. This clinical case confirms the feasibility of therapy with emollient-plus agents, as it was possible to achieve the correction of epidermal barrier dysfunction and significant clinical effect.

1. Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21(1):21–40. doi: https://doi.org/10.1038/s41573-021-00266-6

2. Esaki H, Brunner PM, Renert-Yuval Y, et al. Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. J Allergy Clin Immunol. 2016;138(6):1639–1651. doi: https://doi.org/10.1016/j.jaci.2016.07.013

3. Maintz L, Bieber T, Simpson HD, Demessant-Flavigny AL. From skin barrier dysfunction to systemic impact of atopic dermatitis: implications for a precision approach in dermocosmetics and medicine. J Pers Med. 2022;12(6):893. doi: https://doi.org/10.3390/jpm12060893

4. Araviiskaia E, Pincelli C, Sparavigna A, Luger T. The Role of a Novel Generation of Emollients, ‘Emollients Plus’, in Atopic Dermatitis. Clin Cosmet Investig Dermatol. 2022;15:2705–2719. doi: https://doi.org/10.2147/CCID.S389697

5. Siegfried E, Simpson EL, Boguniewicz M, et al. Dupilumab treatment provides long-term improvement in itch in pediatric patients with moderate-to-severe atopic dermatitis over 1 year. British Journal of Dermatology. 2024;190(Suppl 2):ii56–ii57. doi: https://doi.org/10.1093/bjd/ljad498.058

6. Magnolo N, Jaenicke T, Tsianakas A, et al. Comparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment: A randomized controlled trial. J Eur Acad Dermatol Venereol. 2023;37(Suppl 5): 18–26. doi: https://doi.org/10.1111/jdv.18949

7. Murashkin NN, NamazovaBaranova LS, Opryatin LA, et al. Biologic Therapy of Moderate and Severe Forms of Atopic Dermatitis in Children. Voprosy sovremennoi pediatrii — Current Pediatrics. 2020;19(6):432–443. (In Russ). doi: https://doi.org/10.15690/vsp.v19i6.2145

8. Grobe W, Bieber T, Novak N. Pathophysiology of atopic dermatitis. J Dtsch Dermatol Ges. 2019;17(4):433–440. doi: https://doi.org/10.1111/ddg.13819

9. Nakahara T, Kido-Nakahara M, Tsuji G, Furue M. Basics and recent advances in the pathophysiology of atopic dermatitis. J Dermatol. 2020;48(2):130–139. doi: https://doi.org/10.1111/1346-8138.15664

10. Yang G, Seok JK, Kang HC, et al. Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis. Int J Mol Sci. 2020;21(8):2867. doi: https://doi.org/10.3390/ijms21082867

11. Halling-Overgaard AS, Kezic S, Jakasa I, et al. Skin absorption through atopic dermatitis skin: A systematic review. Br J Dermatol. 2017;177(1):84–106. doi: https://doi.org/10.1111/bjd.15065

12. Zaniboni MC, Samorano LP, Orfali RL, Aoki V. Skin barrier in atopic dermatitis: Beyond filaggrin. Bras Dermatol. 2016;91(4):472–478. doi: https://doi.org/10.1590/abd1806-4841.20164412

13. McLoughlin IJ, Wright EM, Tagg JR, et al. Skin MicrobiomeThe Next Frontier for Probiotic Intervention. Probiotics Antimicrob Proteins. 2022;14(4):630–647. doi: https://doi.org/10.1007/s12602-021-09824-1

14. Mahe YF, Perez MJ, Tacheau C, et al. A new Vitreoscilla filiformis extract grown on spa water-enriched medium activates endogenous cutaneous antioxidant and antimicrobial defenses through a potential toll-like receptor 2/protein kinase C, zeta transduction pathway. Clin Cosmet Investig Dermatol. 2013;6:191–196. doi: https://doi.org/10.2147/CCID.S47324

15. Ch’ng CC. Rebalancing of the skin microbiome with an emollient ‘plus’ for effective management of atopic dermatitis: A mini review. Med J Malaysia. 2024;79(2):203–205.

16. Zelenkova H, Kerob D, Salah S, Demessant-Flavigny AL. Impact of daily use of emollient ‘plus’ on corticosteroid consumption in patients with atopic dermatitis: An open, randomized controlled study. J Eur Acad Dermatol Venereol. 2023;37(Suppl 5):27–34. doi: https://doi.org/10.1111/jdv.18947

17. Allergiya u detei: ot teorii — k praktike. Namazova-Baranova LS, ed. Moscow: Union of Pediatricians of Russia; 2010–2011. 667 p. (In Russ).

18. Naruzhnaya terapiya i ukhod za kozhei pri atopicheskom dermatite u detei: Practical guideline for doctors. Kaznacheeva LF, ed. Novosibirsk; 2003. 24 p. (In Russ).